Pancreatic Cancer Research

ResearcherTongji UniversityNo recent work listed

Xingpeng Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1709-7518; OpenAlex author ID A5082863681. Sources: ClinicalTrials.gov.

Their work

Papers
18 (first author 0, last author 8)
Trials
1
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2011: 3 papers · 2012: 2 papers · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 5 papers, 1 trial · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 2 papers

Papers 18

  1. Retraction Note: Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis. Last author DOI 10.1186/s13046-023-02595-3↗
  2. Suppression of Wnt/β-catenin Signaling in PDAC via METTL16-mediated N6-methyladenosine Modification of DVL2. Co-author DOI 10.7150/jca.85860↗
  3. RELA-induced MiR-21 Exerts Oncogenic Effects on PDAC via Targeting of ARHGAP24. Co-author DOI 10.7150/jca.73690↗
  4. Knockdown of ISOC1 suppresses cell proliferation in pancreatic cancer in vitro. Last author DOI 10.3892/ol.2019.10082↗
  5. Identification of Sox6 as a regulator of pancreatic cancer development. Co-author DOI 10.1111/jcmm.13470↗
  6. Cyclooxygenase-2 induces angiogenesis in pancreatic cancer mediated by prostaglandin E2. Co-author DOI 10.3892/ol.2018.8786↗
  7. The circadian clock gene Bmal1 acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway. Co-author DOI 10.1016/j.canlet.2015.12.002↗
  8. HIC1 attenuates invasion and metastasis by inhibiting the IL-6/STAT3 signalling pathway in human pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.04.013↗
  9. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-15-2068↗
  10. Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis. Last author DOI 10.1186/s13046-016-0301-7↗
  11. [MiR-183 Regulates Proliferation of SW1990 Pancreatic Cancer Cell Line by Targeting PDCD4]. Last author PMID 28598081↗
  12. Identification of dysregulated pathways associated with pancreatic cancer by survival analysis. Last author DOI 10.3892/mmr.2014.2693↗
  13. Net expression inhibits the growth of pancreatic ductal adenocarcinoma cell PL45 in vitro and in vivo. Co-author DOI 10.1371/journal.pone.0057818↗
  14. Genome-wide screening reveals an EMT molecular network mediated by Sonic hedgehog-Gli1 signaling in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0043119↗
  15. Prognostic significance of annexin A1 expression in pancreatic ductal adenocarcinoma. Last author DOI 10.7314/apjcp.2012.13.9.4707↗
  16. Resveratrol inhibits proliferation and induces apoptosis through the hedgehog signaling pathway in pancreatic cancer cell. Co-author DOI 10.1159/000333542↗
  17. Identification of RegIV as a novel GLI1 target gene in human pancreatic cancer. Last author DOI 10.1371/journal.pone.0018434↗
  18. Expression of DNMT1 and DNMT3a are regulated by GLI1 in human pancreatic cancer. Last author DOI 10.1371/journal.pone.0027684↗

Trials 1

  1. K-001 Treatment of Advanced Pancreatic Cancer: Clinical Trial of Monotherapy's Tolerability Study director NCT02720666↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guoyong Hu · 7 shared papers, 2011–2023 · strength 0.46
  2. Baiwen Li · 3 shared papers, 2013–2023 · strength 0.38
  3. Congying Chen · 4 shared papers, 2016–2023 · strength 0.36
  4. Ni Xie · 2 shared papers, 2022–2023 · strength 0.34
  5. Lanting Yu · 2 shared papers, 2022–2023 · strength 0.34
  6. Lijuan Yang · 5 shared papers, 2011–2023 · strength 0.32
  7. Yue Zeng · 2 shared papers, 2016–2023 · strength 0.25
  8. Weiliang Jiang · 4 shared papers, 2016–2018 · strength 0.24
  9. Rong Wan · 4 shared papers, 2016–2018 · strength 0.24
  10. Xuanfu Xu · 5 shared papers, 2011–2018 · strength 0.19
  11. Li Huang · 3 shared papers, 2016–2018 · strength 0.19
  12. Li Huang · 1 shared paper, 2023 · strength 0.17
  13. Haoran Xie · 1 shared paper, 2022 · strength 0.15
  14. Qiuyan Zhao · 1 shared paper, 2022 · strength 0.15
  15. Qiong-Ying Yuan · 2 shared papers, 2015–2018 · strength 0.15
  16. Maochun Tang · 1 shared paper, 2019 · strength 0.12
  17. Yan Fang Zhao · 1 shared paper, 2019 · strength 0.12
  18. Cheng Li · 1 shared paper, 2019 · strength 0.12
  19. Feng Wang · 4 shared papers, 2011–2012 · strength 0.12
  20. Chuangao Xie · 2 shared papers, 2012–2018 · strength 0.11
  21. Bin Hu · 2 shared papers, 2016 · strength 0.11
  22. Chuanyong Guo · 4 shared papers, 2011–2012 · strength 0.10
  23. Jiamin Chen · 1 shared paper, 2018 · strength 0.09
  24. Litao Jia · 1 shared paper, 2018 · strength 0.09
  25. Jianting Cai · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.